Whitehawk Therapeutics (WHWK) Stock: Buy, Sell, or Hold?
WHWK - Whitehawk Therapeutics, Inc. Common Stock
$3.33
0.19 (6.05%)
▲
5d:
+4.39%
30d:
-11.44%
90d:
-9.02%
HOLD
MODERATE Confidence
Analysis Updated: Oct 27, 2026 12:00 AM ET
Earnings: Nov 05, 2026
7d
Get Alerted When WHWK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: WHWK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: WHWK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: WHWK is currently trading at $3.33, which is considered fair relative to its 30-day fair value range of $3.13 to $3.80.
Technical Outlook: Technically, WHWK is in a downtrend. The price is approaching resistance at $3.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.71 (+131.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, WHWK is in a downtrend. The price is approaching resistance at $3.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.71 (+131.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.13 -
$3.80
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- BULLISH: Trading 131.7% below Wall St target ($7.71)
- NEUTRAL: Bottoming setup forming (57/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$3.13 -
$3.80
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.37
(11.1%)
Support & Resistance Levels
Support Level
$2.85
Resistance Level
$3.37
Current Trend
Downtrend
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.37
Wall Street Target
$7.71
(+131.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 28, 2026 1:42 AM ET
Data refreshes hourly during market hours. Next update: 2:42 AM
Data refreshes hourly during market hours. Next update: 2:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is WHWK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$107 | 59 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 65 BUY |
|
ABVX
Abivax SA American Depos… |
STRONG BUY
12 analysts |
$164 | 69 BUY |